Dioseve, a Tokyo-based biotech startup working in the ART (assisted reproductive technology) space has raised around $3M (400M JPY) to re-engineer oocyte development. The round was led by ANRI with participation from Coral Capital.
The company’s technology, DIO (Directly Induced Oocyte), is capable of producing a larger yield of fertilizable egg cells at minimal cost in a fraction of the time. Dioseve’s goal is to create state-of-the-art solutions to a myriad of problems surrounding pregnancy, including infertility as a result of age and hereditary disorders.
